Cortechs.ai | New Product from Cortechs.ai: PETQuant for Research Use

New Product from Cortechs.ai: PETQuant for Research Use

PQ_head_reversed-01.pngOn March 9, 2016, Cortechs.ai launched a new research product: PETQuant™. PETQuant provides automated and fast post-acquisition analyses of PET brain studies to quantify subregional tracer binding in native patient brain space, and is compatible with metabolic (FDG) and amyloid-based (florbetapir) tracers.

PETQuant expands the use of NeuroQuant®’s proven and trusted segmentation technology by offering an additional research tool in the evaluation of neurodegenerative dementias, such as Alzheimer’s disease and frontotemporal dementia.

Fast, Accurate and Simplified Quantitative Phenotyping
PETQuant enables clinical researchers to perform post-acquisition analyses of PET brain studies to quantify subregional tracer binding in native patient brain space

Powered by NeuroQuant
PET tracer bindings are accurately localized to brain structures identified by NeuroQuant 3D T1 MRI segmentation

Completely Automatic
PETQuant offers fully automated and consistent results

Fast and Reliable Quantitative Data
In about 10 minutes, PETQuant returns a complete report with color overlay and quantitative information for 46 brain structures, for both left and right hemispheres

Amyloid Deposition and Metabolism Analysis
PETQuant provides two separate reports that correspond to the PET tracer used; choose between metabolic (FDG) and amyloid-based (florbetapir) analysis reports

Simplified and Easy-to-Read
Color-coded graphical presentation simplifies quantitative reads

Available Anytime, Anywhere
Secure, cloud-based system provides access anytime, from virtually anywhere

This version of PETQuant is for research purposes only.

For more information on PETQuant or to schedule a demo, visit cortechs.ai/petquant or contact us.

More Resources

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.

09/16/2025

OnQ Prostate for Focal Therapy

Read how OnQ Prostate supports focal therapy by personalizing prostate cancer care for patients while minimizing the risks associated with it.

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage
Scroll to Top